Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
作者信息
Emens L A, Adams S, Barrios C H, Diéras V, Iwata H, Loi S, Rugo H S, Schneeweiss A, Winer E P, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui S Y, Schmid P
机构信息
University of Pittsburgh Medical Center Hillman Cancer Center and Department of Medicine, Pittsburgh, USA.
Breast Cancer Center, and Department of Medicine, New York University Langone Health, Perlmutter Cancer Center, New York, USA.
出版信息
Ann Oncol. 2021 Dec;32(12):1650. doi: 10.1016/j.annonc.2021.10.002. Epub 2021 Nov 2.
PMID:34740469
Abstract
摘要
Zotero 插件